Tempest Therapeutics is expected to report a Q3 2026 net loss of $0.32 per share on zero revenue, with the stock currently trading at $1.42, significantly below the consensus analyst price target of $8.50.
Investors are primarily focused on the development timeline and funding strategy for the planned Phase 3 pivotal study of TPST-1120 in first-line hepatocellular carcinoma.
Recent updates highlighted positive alignment with the FDA regarding trial design and the potential for a strategic partnership to support late-stage clinical costs.
With the company continuing to burn capital for research and development, the remaining cash runway will be a critical factor in maintaining investor confidence through upcoming clinical milestones.